Semaglutide patent in India expires in March 2026, enabling over 50 branded generic versions to enter the market, likely ...

This article was reviewed by Darragh O’Carroll, MD. Key takeaways: Semaglutide nausea is common: About 20 percent of Ozempic® ...

How Long It Lasts and Tips to Reduce It This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Nausea is the most ...

A case series reports dysesthesia and allodynia in patients treated with semaglutide and tirzepatide, suggesting a possible dose related to sensory adverse effect.

An increased risk for ischemic optic neuropathy may be associated with formulation- and dose-dependent GLP-1 receptor agonist use.

The drug behind Ozempic has been found to restore joint cartilage in osteoarthritis, through a mechanism that works ...

The generic versions of semaglutide are expected to be at least 50% cheaper— ₹5,000 for a weekly dose—than Ozempic in India .

In the warning letter, the FDA alleged that Novo inadequately responded to observations made after an inspection carried out across January and February of 2025.

Oral semaglutide reduces risk for heart failure events among patients with T2D and preexisting heart failure, according to the SOUL trial.

Ischaemic optic neuropathy (ION) is a rare but vision-threatening complication recently linked to GLP-1 receptor agonists, particularly semaglutide. Using over 30 million reports from the FDA Adverse ...

Medical researchers have discovered that semaglutide may reverse the debilitating tissue damage caused by osteoarthritis, the ...

Mankind Pharma plans to be among the first to enter India's semaglutide market post patent expiry. The company aims to offer ...